Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Drugs

Drug Development for Myalgic Encephalomyelitis and Chronic Fatigue Syndrome (ME and CFS)

FDA is planning a series of activities focused on drug development to treat the symptoms of Myalgic Encephalomyelitis and Chronic Fatigue Syndrome (ME and CFS) in order to explore:

  • The burden of disease that impacts the quality of life for ME and CFS patients;
  • The quantitative outcome measures or endpoints that determine if disease symptoms improve with intervention; and
  • How drug efficacy should be clinically tested based on these endpoints or measurements.

Please send correspondence regarding ME and CFS to ME-CFS-Meeting@fda.hhs.gov.

Activities

Please Note: The list of activities will be updated as each activity is announced.

 

Page Last Updated: 12/11/2014
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.